Finalgel® (Finalgel®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePiroxicamPiroxicam
Similar drugsTo uncover
  • Vero-Piroxicam
    pills inwards 
    VEROPHARM SA     Russia
  • Piroxicam
    gel externally 
    ATOLL, LLC     Russia
  • Piroxicam
    capsules inwards 
    PRODUCTION OF MEDICINES, LTD.     Russia
  • Piroxicam
    gel externally 
    VERTEKS, AO     Russia
  • Piroxicam
    capsules inwards 
    Sopharma, AO     Bulgaria
  • Piroxicam-OBL
    capsules inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Piroxicam-Acry®
    capsules inwards 
    AKRIKHIN HFK, JSC     Russia
  • Finalgel®
    gel externally 
    Boehringer Ingelheim International GmbH     Germany
    • Dosage form: & nbsp

    Gel for external use.

    Composition:

    In 100 g of gel contains: active substance piroxicam - 0.5 g

    Excipients: propylene glycol 15.00 g; isopropanol 5.00 g; macrogol glyceryl cocoate (cetyl NE) 2.00 g; hypromellose (hydroxypropylmethylcellulose) 2.20 g; sodium hydroxide 0.24 g; sodium disulfite (sodium metabisulphite) 0.10 g; potassium dihydrogen phosphate 0.50 g; purified water 74.46 g.

    Description:

    Transparent or slightly opalescent light yellow gel with a faint smell of isopropyl alcohol.

    Pharmacotherapeutic group:Non-steroidal anti-inflammatory drug (NSAID)
    ATX: & nbsp

    M.02.A.A.07   Piroxicam

    Pharmacodynamics:

    Has anti-inflammatory, analgesic, local cooling effect. The non-selective inhibition of cyclooxygenase 1 and 2.

    Pharmacokinetics:

    After applying 4 g of the drug on the skin, the maximum concentration of piroxicam in the systemic circulation is 149.2 ± 30.3 ng / ml.

    Indications:

    Pain syndrome: ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, juvenile chronic arthritis, tendonitis, tendovaginitis, shoulder-scapular syndrome; sports injuries (bruises, dislocations, ligament damage).

    Contraindications:

    • hypersensitivity to piroxicam or other components of the drug;
    • hypersensitivity to acetylsalicylic acid or other NSAIDs;
    • pregnancy (III trimester);
    • kidney failure;
    • age to 14 years.

    Carefully:

    Bronchial asthma, allergic rhinitis, recurrent nasal polyposis and paranasal sinuses, chronic obstructive pulmonary disease or chronic pulmonary infections.

    Pregnancy and lactation:

    Finalgel® should be used with caution during the first and second trimester of pregnancy.

    Piroxicam in small amounts can penetrate into breast milk, so it is not recommended to use the drug during lactation.

    Dosing and Administration:

    Outwardly.Adults and children over 14 years of age per 1 g of gel (approximately the size of the hazelnut) 3-4 times a day. The gel should be applied to the skin over the affected area and rubbed gently.

    The duration of treatment depends on the severity of the symptoms and on average is 2-3 weeks with tendinitis, tendovaginitis and shoulder-and-shoulder syndrome; 1-2 weeks with sports injuries.

    Side effects:

    • local skin irritation (inflammation, redness, hives, itching, peeling);
    • local allergic reactions.

    Overdose:

    When using the drug in doses exceeding the recommended, in single cases, the occurrence of systemic side effects is not excluded: headache; disorders of the gastrointestinal tract (nausea, pain in the epigastric region); Shortness of breath.

    A single case of interstitial nephritis with functional renal failure and nephrotic syndrome is described.

    In case of symptoms of overdose, the drug should be discontinued and consult a doctor.

    Treatment: symptomatic.

    Interaction:

    It is not known.

    Special instructions:

    Patients suffering from bronchial asthma, allergic rhinitis, recurrent polyposis of the nose and paranasal sinuses,chronic obstructive pulmonary diseases or chronic pulmonary infections, are generally more sensitive to the use of NSAIDs. Asthma attacks may occur in these patients, Quincke's edema may appear, and urticaria may develop.

    Do not apply gel to damaged skin, including open wounds. Avoid contact with eyes.

    Effect on the ability to drive transp. cf. and fur:

    It is not known.

    Form release / dosage:Gel for external use 0,5%.
    Packaging:

    35 g or 50 g in an aluminum tube, covered with a plastic cap with a punch for the membrane. The tube with instruction for use is placed in a cardboard box.

    Storage conditions:

    At a temperature not higher than 25 ° C, out of the reach of children.

    Shelf life:

    3 years. 6 months from the date of opening the tube. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N016210 / 01
    Date of registration:15.02.2010
    The owner of the registration certificate:Boehringer Ingelheim International GmbHBoehringer Ingelheim International GmbH Germany
    Manufacturer: & nbsp
    Representation: & nbspBehringer Ingelheim, LLCBehringer Ingelheim, LLC
    Information update date: & nbsp12.08.2015
    Illustrated instructions
      Instructions
      Up